← Leaderboards
Robert Smith Oakes
Baltimore Va Medical Center
$0
Attributed
$0
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2020–24$1$1$1$0$0
'20
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 1
By mechanism
IK2$0 · 1
Top collaborators
No co-investigators on record.
Most similar at Baltimore Va Medical Center
Same institution · by research overlap
- Christopher M Jewell$8,528,150
- Brajesh K Lal$19,608,955
- Thomas L Clemens$12,391,839
- Kamal D. Moudgil$4,222,813
- Jian-Ying Wang$21,042,684
Others in their field
Other Emerging Leaders on “Cell Type”
- Evan Z Macosko · Broad Institute, Inc.$36,871,464
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$20,250,477
- Thomas Denny · Duke University$19,381,749
- Tomasz Nowakowski · University Of California, San Francisco$18,472,946
- Hemali Phatnani · New York University School Of Medicine$18,358,586
- Rui M. Costa · Columbia University Health Sciences$13,762,381
Research focus
Cell TypeClinicCareer DevelopmentAffectAllergy ShotCellsAntigensAnimal ModelAutoantigensAllergensAutoimmune DiseasesAntibodiesAntigen-Presenting CellsAutoimmunityAutomobile DrivingAxonAntigen TargetingBiological MarkersBiological Response ModifiersBlindnessB-LymphocytesBrainCareerClinical Data
Grant awards (5)
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple Sclerosis$0
IK2 · FY2024 · VA · contact PI
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple Sclerosis$0
IK2 · FY2023 · VA · contact PI
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple Sclerosis$0
IK2 · FY2022 · VA · contact PI
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple Sclerosis$0
IK2 · FY2021 · VA · contact PI
Leveraging nanotechnology and skin delivery to drive selective immune tolerance for Multiple Sclerosis$0
IK2 · FY2020 · VA · contact PI